| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Biotech | IPO Date | Headquarters | Ticker | Shs Sold | IPO $/Sh | IPO Proceeds | Insider % | Insider Dollars | Insider Optional | IPO SEC Link | Date Founded | Pre-IPO Shares | IPO Pre- Money | Shs Post-IPO | Post IPO Mkt Cap | Most Advanced | Platform | Therapeutic Area | |||||||
2 | Acumen Pharmaceuticals | 30-Jun-21 | Virginia | ABOS | 10.00 | $16.00 | $160.00 | Link | 1996 | 28.65 | $458.4 | 38.7 | $618.40 | Phase I | Monoclonals | CNS, Alzheimers MOA | ||||||||||
3 | Aerovate Therapeutics | 29-Jun-21 | Mass | AVTE | 8.68 | $14.00 | $121.52 | Link | 2018 | 14.40 | $201.6 | 23.1 | $323.12 | Phase I | None | Cardio pulmonary formulation | ||||||||||
4 | Acurx Pharmaceuticals | 24-Jun-21 | New York | ACXP | 2.50 | $6.00 | $15.00 | Link | 2017 | 7.00 | $42.0 | 9.5 | $57.00 | Phase II | None | Antibiotics MOA | ||||||||||
5 | Alpha Teknova | 24-Jun-21 | NorCal | TKNO | 6.00 | $16.00 | $96.00 | Link | 1996 | 21.10 | $337.6 | 27.1 | $433.60 | Mkt | Cell culture | Reagents | ||||||||||
6 | Elevation Oncology | 24-Jun-21 | New York | ELEV | 6.25 | $16.00 | $100.00 | Link | 2019 | 16.60 | $265.6 | 22.9 | $365.60 | Phase II | None | Cancer MOA | ||||||||||
7 | GH Research | 24-Jun-21 | Ireland | GHRS | 10.00 | $16.00 | $160.00 | Link | 2018 | 40.50 | $648.0 | 50.5 | $808.00 | Phase II | None | CNS Psychiatric | ||||||||||
8 | Graphite Bio | 24-Jun-21 | NorCal | GRPH | 14.00 | $17.00 | $238.00 | Link | 2017 | 42.00 | $714.0 | 56.0 | $952.00 | Preclinical | Gene editing | Genetic diseases | ||||||||||
9 | Miromatrix Medical | 23-Jun-21 | Minnesota | MIRO | 4.80 | $9.00 | $43.20 | Link | 2009 | 13.40 | $120.6 | 18.2 | $163.80 | Preclinical | Bioengineered organs | Transplantation | ||||||||||
10 | Ambrx Biopharma | 17-Jun-21 | SoCal | AMAM | 7.00 | $18.00 | $126.00 | Link | 2003 | 30.70 | $552.6 | 37.7 | $678.60 | Phase III | Monoclonal ADC | Cancer MOA | ||||||||||
11 | ATAI Life Sciences | 17-Jun-21 | Netherlands | ATAI | 15.00 | $15.00 | $225.00 | Link | 2018 | 137.60 | $2,064.0 | 152.6 | $2,289.00 | Phase II | None | CNS Psychiatric | ||||||||||
12 | Codex DNA | 17-Jun-21 | SoCal | DNAY | 6.67 | $16.00 | $106.72 | Link | 2011 | 21.50 | $344.0 | 28.2 | $450.72 | Mkt | Synthetic biology | Devices & reagents | ||||||||||
13 | Cyteir Therapeutics | 17-Jun-21 | Mass | CYT | 7.40 | $18.00 | $133.20 | Link | 2012 | 27.10 | $487.8 | 34.5 | $621.00 | Phase I | Synthetic lethality | Cancer MOA | ||||||||||
14 | Lyell Immunopharma | 16-Jun-21 | NorCal | LYEL | 25.00 | $17.00 | $425.00 | Link | 2018 | 217.80 | $3,702.6 | 242.8 | $4,127.60 | Preclinical | T cell immunotherapy | Cancer MOA | ||||||||||
15 | Verve Therapeutics | 16-Jun-21 | Mass | VERV | 14.00 | $19.00 | $266.00 | 28% | $74.48 | Yes | Link | 2018 | 32.10 | $609.9 | 46.1 | $875.90 | Preclinical | Gene editing | Cardiiovascular MOA | |||||||
16 | Molecular Partners AG | 15-Jun-21 | Switzerland | MOLN | 3.00 | $21.25 | $63.75 | Link | 2004 | 29.20 | $620.5 | 32.2 | $684.25 | Phase III | Monoclonal ADC | Infection & cancer MOA | ||||||||||
17 | Alzamend Neuro | 14-Jun-21 | Florida | ALZN | 2.50 | $5.00 | $12.50 | 80% | $10.00 | Link | 2016 | 82.40 | $412.0 | 84.9 | $424.50 | Preclinical | None | Alzheimer's | ||||||||
18 | Janux Therapeutics | 10-Jun-21 | SoCal | JANX | 11.40 | $17.00 | $193.80 | Link | 2017 | 28.50 | $484.5 | 39.9 | $678.30 | Preclinical | T cell immunotherapy | Cancer MOA | ||||||||||
19 | Centessa Pharmaceuticals | 27-May-21 | London | CNTA | 16.50 | $20.00 | $330.00 | Link | 2020 | 70.70 | $1,414.0 | 87.2 | $1,744.00 | Phase III | None | Multiple diseases | ||||||||||
20 | Day One Biopharmaceuticals | 26-May-21 | NorCal | DAWN | 10.00 | $16.00 | $160.00 | Link | 2018 | 50.40 | $806.4 | 60.4 | $966.40 | Phase II | None | Cancer MOA | ||||||||||
21 | Vera Therapeutics | 13-May-21 | NorCal | VERA | 4.35 | $11.00 | $47.85 | Link | 2016 | 16.13 | $177.4 | 20.5 | $225.28 | Phase II | None | Autoimmune diseases | ||||||||||
22 | Anebulo Pharmaceuticals | 06-May-21 | Texas | ANEB | 3.00 | $7.00 | $21.00 | 30% | $6.30 | Link | 2020 | 20.27 | $141.9 | 23.3 | $162.89 | Phase I | None | CNS, Addiction | ||||||||
23 | Talaris Therapeutics | 06-May-21 | Kentucky | TALS | 8.83 | $17.00 | $150.03 | Link | 2002 | 32.42 | $551.1 | 41.2 | $701.17 | Phase II | cell therapy | Kidney disease | ||||||||||
24 | Valneva | 05-May-21 | France | VALN | 3.54 | $26.41 | $93.49 | Link | 1999 | 45.40 | $1,199.0 | 48.9 | $1,292.51 | Phase II | Vaccine design | Lyme disease vaccine | ||||||||||
25 | Vaccitech | 29-Apr-21 | Oxford UK | VACC | 6.50 | $17.00 | $110.50 | Link | 2016 | 27.56 | $468.5 | 34.1 | $579.02 | Phase II | Drug design | Infections & Cancer MOA | ||||||||||
26 | Werewolf Therapeutics | 29-Apr-21 | Mass | HOWL | 7.50 | $16.00 | $120.00 | Link | 2017 | 20.04 | $320.6 | 27.5 | $440.64 | Preclinical | Drug design | Cancer MOA | ||||||||||
27 | Protagenic Therapeutics | 26-Apr-21 | New York | PTIX | 3.18 | $4.15 | $13.20 | Link | 2006 | 10.60 | $44.0 | 13.8 | $57.19 | Preclinical | None | CNS, Depression | ||||||||||
28 | Impel NeuroPharma | 22-Apr-21 | Seattle | IMPL | 5.33 | $15.00 | $79.95 | Link | 2008 | 14.08 | $211.2 | 19.4 | $291.15 | Filed | Nasal delivery | CNS, Migraines | ||||||||||
29 | Rain Therapeutics | 22-Apr-21 | NorCal | RAIN | 7.35 | $17.00 | $124.95 | Link | 2017 | 18.62 | $316.5 | 26.0 | $441.49 | Phase I | Drug design | Cancer MOA | ||||||||||
30 | Zymergen | 21-Apr-21 | NorCal | ZY | 16.13 | $31.00 | $500.03 | Link | 2013 | 81.81 | $2,536.1 | 97.9 | $3,036.14 | Mkt | Microbial manu | Biofilm | ||||||||||
31 | Akoya Biosciences | 15-Apr-21 | Mass | AKYA | 6.58 | $20.00 | $131.60 | Link | 2015 | 29.11 | $582.2 | 35.7 | $713.80 | Mkt | Diagnostic | Biomarkers | ||||||||||
32 | Biomea Fusion | 15-Apr-21 | NorCal | BMEA | 9.00 | $17.00 | $153.00 | Link | 2017 | 19.77 | $336.1 | 28.8 | $489.09 | Preclinical | Drug design | Cancer MOA | ||||||||||
33 | Recursion Pharmaceuticals | 15-Apr-21 | Salt Lake City | RXRX | 24.24 | $18.00 | $436.32 | 29% | $124.79 | Link | 2013 | 137.92 | $2,482.6 | 162.2 | $2,918.88 | Phase I | Bioinformatics | Multiple | ||||||||
34 | Reneo Pharmaceuticals | 08-Apr-21 | SoCal | RPHM | 6.25 | $15.00 | $93.75 | Link | 2014 | 17.96 | $269.4 | 24.2 | $363.15 | Phase II | Genetic diseases | Mitochondrial diseases | ||||||||||
35 | VectivBio Holding | 08-Apr-21 | Basel | VECT | 7.50 | $17.00 | $127.50 | Link | 2019 | 26.51 | $450.7 | 34.0 | $578.17 | Phase III | rare diseases | GI diseases | ||||||||||
36 | Achilles Therapeutics | 30-Mar-21 | London | ACHL | 9.75 | $18.00 | $175.50 | Link | 2016 | 30.87 | $555.7 | 40.6 | $731.16 | Phase I/II | Drug design | Cancer MOA | ||||||||||
37 | Design Therapeutics | 25-Mar-21 | SoCal | DSGN | 12.00 | $20.00 | $240.00 | Link | 2017 | 41.82 | $836.4 | 53.8 | $1,076.40 | Preclinical | Genetic diseases | Muscle wasting | ||||||||||
38 | Edgewise Therapeutics | 25-Mar-21 | Colorado | EWTX | 11.00 | $16.00 | $176.00 | Link | 2017 | 36.57 | $585.1 | 47.6 | $761.12 | Phase I | rare diseases | Muscle wasting | ||||||||||
39 | Ikena Oncology | 25-Mar-21 | Mass | IKNA | 7.81 | $16.00 | $124.96 | Link | 2016 | 26.78 | $428.5 | 34.6 | $553.44 | Preclinical | Drug design | Cancer MOA | ||||||||||
40 | Lava Therapeutics | 24-Mar-21 | Netherlands | LATX | 6.70 | $15.00 | $100.50 | Link | 2016 | 18.65 | $279.8 | 25.4 | $380.25 | Preclinical | Bi-specific Abs | Cancer MOA | ||||||||||
41 | Universe Pharmaceuticals | 22-Mar-21 | China | UPC | 5.00 | $5.00 | $25.00 | Link | 1998 | 16.00 | $80.0 | 21.0 | $105.00 | Mkt | Natural products | Inflammation | ||||||||||
42 | Connect Biopharma | 18-Mar-21 | China | CNTB | 11.25 | $17.00 | $191.25 | Link | 2012 | 67.07 | $1,140.2 | 78.3 | $1,331.44 | Phase II | Cellular screening | Inflammation | ||||||||||
43 | Finch Therapeutics | 18-Mar-21 | Mass | FNCH | 7.50 | $17.00 | $127.50 | Link | 2014 | 39.65 | $674.1 | 47.2 | $801.55 | Phase II | Microbiome | Infections | ||||||||||
44 | Instil Bio | 18-Mar-21 | Texas | TIL | 16.00 | $20.00 | $320.00 | Link | 2018 | 109.81 | $2,196.2 | 125.8 | $2,516.20 | Preclinical | cell therapy | Cancer MOA | ||||||||||
45 | Gain Therapeutics | 17-Mar-21 | Maryland | GANX | 3.64 | $11.00 | $40.04 | Link | 2017 | 7.69 | $84.6 | 11.3 | $124.63 | Lead | Genetic diseases | Lysosomal disorders | ||||||||||
46 | Longboard Pharmaceuticals | 11-Mar-21 | SoCal | LBPH | 5.00 | $16.00 | $80.00 | Link | 2020 | 11.92 | $190.7 | 16.9 | $270.72 | Phase I | None | CNS | ||||||||||
47 | Prometheus Biosciences | 11-Mar-21 | SoCal | RXDX | 10.00 | $19.00 | $190.00 | Link | 2016 | 27.25 | $517.8 | 37.3 | $707.75 | Phase I | None | GI diseases, IBD | ||||||||||
48 | Longeveron | 12-Feb-21 | Florida | LGVN | 2.66 | $10.00 | $26.60 | Link | 2014 | 16.04 | $160.4 | 18.7 | $187.00 | Phase II | cell therapy | Aging frailty | ||||||||||
49 | Decibel Therapeutics | 11-Feb-21 | Mass | DBTX | 7.06 | $18.00 | $127.08 | Link | 2013 | 17.24 | $310.3 | 24.3 | $437.40 | Preclinical | Gene Therapy | Hearing & balance disorders | ||||||||||
50 | NexImmune | 11-Feb-21 | Maryland | NEXI | 6.47 | $17.00 | $109.99 | Link | 2011 | 15.08 | $256.4 | 21.6 | $366.35 | Phase I | Drug design | Cancer MOA | ||||||||||
51 | Talis Biomedical | 11-Feb-21 | NorCal | TLIS | 13.80 | $16.00 | $220.80 | Link | 2010 | 39.54 | $632.6 | 53.3 | $853.44 | EUA filed | Diagnostic | Respiratory infections | ||||||||||
52 | Angion Biomedica | 09-Feb-21 | New York | ANGN | 5.00 | $16.00 | $80.00 | Link | 1998 | 22.16 | $354.6 | 27.2 | $434.56 | Phase III | None | Kidney disease | ||||||||||
53 | Biophytis SA | 09-Feb-21 | Paris | BPTS | 1.20 | $16.75 | $20.10 | Link | 2006 | 10.08 | $168.8 | 11.3 | $188.94 | Phase II | None | Neuro-muscular diseases | ||||||||||
54 | Vallon Pharmaceuticals | 09-Feb-21 | Pennsylvania | VLON | 2.25 | $8.00 | $18.00 | Link | 2018 | 4.51 | $36.1 | 6.8 | $54.08 | Phase I | Abuse deterent del | CNS | ||||||||||
55 | Adagene | 08-Feb-21 | China | ADAG | 7.35 | $19.00 | $139.65 | Link | 2011 | 34.82 | $661.6 | 42.2 | $801.23 | Phase I | Drug design | Cancer MOA | ||||||||||
56 | Vor Biopharma | 05-Feb-21 | Mass | VOR | 9.83 | $18.00 | $176.94 | Link | 2015 | 25.82 | $464.8 | 35.7 | $641.70 | Preclinical | cell therapy | Cancer MOA | ||||||||||
57 | Bolt Biotherapeutics | 04-Feb-21 | NorCal | BOLT | 11.50 | $20.00 | $230.00 | Link | 2015 | 23.02 | $460.4 | 34.5 | $690.40 | Phase I/II | Monoclonal ADC | Cancer MOA | ||||||||||
58 | Evaxion Biotech | 04-Feb-21 | Denmark | EVAX | 10.00 | $3.00 | $30.00 | Link | 2008 | 16.20 | $48.6 | 26.2 | $78.60 | Phase I/II | Drug design | Cancer MOA | ||||||||||
59 | Immunocore | 04-Feb-21 | England | IMCR | 9.94 | $26.00 | $258.44 | Link | 2007 | 32.36 | $841.4 | 42.3 | $1,099.80 | Phase III | Bispecific Mabs | Cancer MOA | ||||||||||
60 | Lucira Health | 04-Feb-21 | NorCal | LHDX | 9.00 | $17.00 | $153.00 | Link | 2013 | 27.96 | $475.3 | 37.0 | $628.32 | EUA granted | Diagnostic | Respiratory infections | ||||||||||
61 | Pharvaris BV | 04-Feb-21 | Netherlands | PHVS | 8.27 | $20.00 | $165.40 | Link | 2015 | 23.57 | $471.4 | 31.8 | $636.80 | Phase I | rare diseases | angioedema | ||||||||||
62 | Terns Pharmaceuticals | 04-Feb-21 | NorCal | TERN | 7.50 | $17.00 | $127.50 | Link | 2016 | 16.47 | $280.0 | 24.0 | $407.49 | Phase II | None | Liver disease, NASH | ||||||||||
63 | Landos Biopharma | 03-Feb-21 | Virginia | LABP | 6.25 | $16.00 | $100.00 | Link | 2017 | 32.91 | $526.6 | 39.2 | $626.56 | Phase II | Drug design | Autoimmune diseases | ||||||||||
64 | Sana Biotechnology | 03-Feb-21 | Seattle | SANA | 23.50 | $25.00 | $587.50 | Link | 2018 | 160.31 | $4,007.8 | 183.8 | $4,595.25 | Preclinical | cell therapy | Cancer MOA | ||||||||||
65 | Sensei Biotherapeutics | 03-Feb-21 | Maryland | SNSE | 7.00 | $19.00 | $133.00 | Link | 1999 | 22.56 | $428.6 | 29.6 | $561.64 | Phase II | Bacteriophage Mab | Cancer MOA | ||||||||||
66 | Ortho Clinical Diagnostics | 27-Jan-21 | England | OCDX | 76.00 | $17.00 | $1,292.00 | Link | 2014 | 146.58 | $2,491.9 | 222.6 | $3,783.86 | Mkt | Diagnostic | Multiple | ||||||||||
67 | Cullinan Oncology | 07-Jan-21 | Mass | CGEM | 11.90 | $21.00 | $249.90 | Link | 2016 | 29.50 | $619.5 | 41.4 | $869.40 | Phase I | None | Cancer MOA | ||||||||||
68 | Gracell Biotechnologies | 07-Jan-21 | China | GRCL | 11.00 | $19.00 | $209.00 | Link | 2017 | 54.56 | $1,036.6 | 65.6 | $1,245.64 | Preclinical | cell therapy | Cancer MOA | ||||||||||
69 | Pharming Group | 22-Dec-20 | Netherlands | PHAR | 0.90 | $17.86 | $16.07 | Link | 1988 | 62.91 | $1,123.6 | 63.8 | $1,139.65 | Mkt | Recombinant DNA | Multiple | ||||||||||
70 | BioAtla | 15-Dec-20 | SoCal | BCAB | 10.50 | $18.00 | $189.00 | Link | 2007 | 20.10 | $361.8 | 30.6 | $550.80 | Phase II | Monoclonals | Cancer MOA | ||||||||||
71 | 4D Molecular Therapeutics | 10-Dec-20 | NorCal | FDMT | 8.40 | $23.00 | $193.20 | Link | 2013 | 16.83 | $387.1 | 25.2 | $580.29 | Phase I | Gene Therapy | Ophthalmology | ||||||||||
72 | AbCellera Biologics | 10-Dec-20 | Canada | ABCL | 24.15 | $20.00 | $483.00 | 20% | $96.60 | Yes | Link | 2012 | 241.42 | $4,828.4 | 265.6 | $5,311.40 | Phase III | Drug design | Multiple | |||||||
73 | Nanobiotix | 10-Dec-20 | France | NBTX | 7.30 | $13.50 | $98.55 | Link | 2003 | 26.04 | $351.5 | 33.3 | $450.09 | Mkt in EU | radiotherapy | Cancer | ||||||||||
74 | Sigilon Therapeutics | 03-Dec-20 | Mass | SGTX | 7.00 | $18.00 | $126.00 | Link | 2015 | 23.19 | $417.4 | 30.2 | $543.42 | Phase I | cell therapy | Blood disorders | ||||||||||
75 | Silverback Therapeutics | 03-Dec-20 | Seattle | SBTX | 11.50 | $21.00 | $241.50 | Link | 2016 | 21.57 | $453.0 | 33.1 | $694.47 | Phase I | Monoclonal ADC | Cancer MOA | ||||||||||
76 | Kinnate Biopharma | 02-Dec-20 | SoCal | KNTE | 12.00 | $20.00 | $240.00 | Link | 2018 | 29.53 | $590.6 | 41.5 | $830.60 | Preclinical | Drug design | Cancer MOA | ||||||||||
77 | Maravai LifeSciences | 19-Nov-20 | SoCal | MRVI | 60.00 | $27.00 | $1,620.00 | Link | 2014 | 197.62 | $5,335.7 | 257.6 | $6,955.74 | Mtk | Oligo reagents | Multiple | ||||||||||
78 | Olema Pharmaceuticals | 18-Nov-20 | NorCal | OLMA | 11.00 | $19.00 | $209.00 | Link | 2006 | 27.52 | $522.9 | 38.5 | $731.88 | Phase I | None | Cancer MOA | ||||||||||
79 | Atea Pharmaceuticals | 29-Oct-20 | Mass | AVIR | 12.50 | $24.00 | $300.00 | Link | 2012 | 68.24 | $1,637.8 | 80.7 | $1,937.76 | Phase II | Nucleotides | Antivirals | ||||||||||
80 | SQZ Biotechnologies | 29-Oct-20 | Mass | SQZ | 4.41 | $16.00 | $70.56 | Link | 2013 | 19.56 | $313.0 | 24.0 | $383.52 | Phase I | cell therapy | Cancer & Infection | ||||||||||
81 | Galecto | 28-Oct-20 | Denmark | GLTO | 5.67 | $15.00 | $85.05 | Link | 2019 | 18.92 | $283.8 | 24.6 | $368.85 | Phase II | None | Fibrotic lung disease | ||||||||||
82 | Biodesix | 27-Oct-20 | Colorado | BDSX | 4.00 | $18.00 | $72.00 | Link | 2005 | 22.25 | $400.5 | 26.3 | $472.50 | Mkt | Diagnostic | Lung disease | ||||||||||
83 | Foghorn Therapeutics | 22-Oct-20 | Mass | FHTX | 7.50 | $16.00 | $120.00 | Link | 2015 | 28.20 | $451.2 | 35.7 | $571.20 | Preclinical | Drug design | Cancer MOA | ||||||||||
84 | Abcam plc | 21-Oct-20 | England | ABCM | 8.95 | $17.50 | $156.63 | Link | 1998 | 216.22 | $3,783.9 | 225.2 | $3,940.48 | Mkt | Reagents | Multiple | ||||||||||
85 | Opthea | 16-Oct-20 | Australia | OPT | 8.56 | $13.50 | $115.56 | Link | 1984 | 36.65 | $494.8 | 45.2 | $610.34 | Phase II | None | Eye diseases | ||||||||||
86 | Aligos Therapeutics | 15-Oct-20 | NorCal | ALGS | 10.00 | $15.00 | $150.00 | Link | 2018 | 26.89 | $403.4 | 36.9 | $553.35 | Phase I | oligonucleotides | Viral & liver diseases | ||||||||||
87 | Kiromic Biopharma | 15-Oct-20 | Texas | KRBP | 1.25 | $12.00 | $15.00 | Link | 2006 | 6.08 | $73.0 | 7.3 | $87.96 | Preclinical | Cell / gene-editing | Cancer MOA | ||||||||||
88 | Praxis Precision Med | 15-Oct-20 | Mass | PRAX | 10.00 | $19.00 | $190.00 | Link | 2015 | 26.75 | $508.3 | 36.8 | $698.25 | Phase II | Drug design | CNS diseases | ||||||||||
89 | Tarsus Pharmaceuticals | 15-Oct-20 | SoCal | TARS | 5.50 | $16.00 | $88.00 | Link | 2016 | 13.76 | $220.2 | 19.3 | $308.16 | Phase II/III | None | Eye diseases | ||||||||||
90 | Codiak BioSciences | 13-Oct-20 | Mass | CDAK | 5.50 | $15.00 | $82.50 | Link | 2015 | 13.09 | $196.4 | 18.6 | $278.85 | Phase I | Exosome delivery | Cancer & CNS | ||||||||||
91 | Kronos Bio | 08-Oct-20 | NorCal | KRON | 13.16 | $19.00 | $250.04 | Link | 2017 | 39.88 | $757.7 | 53.0 | $1,007.76 | Phase II | Drug design | Cancer MOA | ||||||||||
92 | Shattuck Labs | 08-Oct-20 | North Carolina | STTK | 11.88 | $17.00 | $201.96 | Link | 2016 | 28.08 | $477.4 | 40.0 | $679.32 | Phase I | Drug design | Cancer MOA | ||||||||||
93 | Spruce Biosciences | 08-Oct-20 | NorCal | SPRB | 6.00 | $15.00 | $90.00 | Link | 2014 | 16.26 | $243.9 | 22.3 | $333.90 | Phase II | None | Endocrine disorders | ||||||||||
94 | Aziyo Biologics | 07-Oct-20 | Maryland | AZYO | 2.94 | $17.00 | $49.98 | 40% | $19.99 | Yes | Link | 2015 | 7.29 | $123.9 | 10.2 | $173.91 | Mkt | Implantable devices | Regenerative medicine | |||||||
95 | C4 Therapeutics | 01-Oct-20 | Mass | CCCC | 9.60 | $19.00 | $182.40 | Link | 2015 | 31.95 | $607.1 | 41.6 | $789.45 | Preclinical | Drug design | Cancer & CNS MOA | ||||||||||
96 | Immunome | 01-Oct-20 | Pennsylvania | IMNM | 3.25 | $12.00 | $39.00 | 51% | $19.89 | Yes | Link | 2006 | 6.78 | $81.4 | 10.0 | $120.36 | Preclinical | Monoclonals | Cancer & Viral MOA | |||||||
97 | Oncorus | 01-Oct-20 | Mass | ONCR | 5.80 | $15.00 | $87.00 | Link | 2015 | 16.05 | $240.8 | 21.9 | $327.75 | Phase I | Drug design | Antivirals MOA | ||||||||||
98 | Orphazyme A/S | 28-Sep-20 | Denmark | ORPH | 7.62 | $11.00 | $83.82 | Link | 2009 | 27.04 | $297.4 | 34.7 | $381.26 | Filed | Heat shock proteins | Orphan diseases | ||||||||||
99 | Greenwich LifeSciences | 24-Sep-20 | Texas | GLSI | 1.26 | $5.75 | $7.25 | Link | 2006 | 10.71 | $61.6 | 12.0 | $68.83 | Phase II | None | Cancer MOA | ||||||||||
100 | Compass Pathways | 21-Sep-20 | England | CMPS | 7.50 | $17.00 | $127.50 | Link | 2017 | 27.31 | $464.3 | 34.8 | $591.77 | Phase II | None | Depression |